On page 857 of the original publication, the following statement contains a technical error.
On page 857 of the original publication, the following statement contains a technical error.
Recently, the FDA approved Nuedexta, a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis or multiple sclerosis.
Correction: Although the FDA approved Nuedexta based on studies in AML and MS, the approved indication was for treatment of pseudobulbar palsy (without restriction to a specific underlying condition). 
